Skip to main content

Affimed N.V. (AFMD)

NASDAQ: AFMD · Delayed Price · USD
6.55
-0.04 (-0.61%)
After-hours:Sep 23, 2021 5:22 PM EDT
6.59
0.25 (3.94%)
At close: Sep 23, 4:00 PM
Market Cap759.10M
Revenue (ttm)34.59M
Net Income (ttm)-50.45M
Shares Out119.73M
EPS (ttm)-0.43
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume455,444
Open6.40
Previous Close6.34
Day's Range6.35 - 6.60
52-Week Range3.09 - 11.74
Beta2.65
AnalystsStrong Buy
Price Target14.75 (+123.8%)
Est. Earnings DateNov 9, 2021

About AFMD

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Europe, and Germany. Its lead product candidate is AFM13, which has completed Phase II clinical study of CD30-positive T-cell lymphoma, and hodgkin lymphoma (HL), as well as is in Phase II clinical trials for peripheral T-cell lymphoma, and transformed mycosis fungoides; that is in Phase I clinical study in combination with adoptive NK cells for CD30-postive lymphomas; and has completed Phase Ib clinical s...

IndustryBiotechnology
IPO DateSep 12, 2014
Employees153
Stock ExchangeNASDAQ
Ticker SymbolAFMD
Full Company Profile

Financial Performance

In 2020, Affimed N.V.'s revenue was 28.36 million, an increase of 32.58% compared to the previous year's 21.39 million. Losses were -41.37 million, 27.8% more than in 2019.

Financial numbers in millions EURFinancial Statements

Analyst Forecast

According to 4 analysts, the average rating for Affimed N.V. stock is "Strong Buy." The 12-month stock price forecast is 14.75, which is an increase of 123.79% from the latest price.

Price Target
$14.75
(123.79% upside)
Analyst Consensus: Strong Buy

News

New Strong Sell Stocks for September 13th

AFMD, DZSI, GMBL, NTRB, and SURF have been added to the Zacks Rank #5 (Strong Sell) List on September 13, 2021.

Other symbols:DZSIGMBLNTRBSURF
1 week ago - Zacks Investment Research

Affimed N.V. (AFMD) Reports Q2 Loss, Lags Revenue Estimates

Affimed N.V. (AFMD) delivered earnings and revenue surprises of -171.43% and -13.79%, respectively, for the quarter ended June 2021.

2 weeks ago - Zacks Investment Research

Affimed Reports Second Quarter 2021 Financial Results and Highlights Operational Progress

HEIDELBERG, Germany, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, toda...

2 weeks ago - GlobeNewsWire

Affimed to Present at Upcoming Investor Conferences

HEIDELBERG, Germany, Aug. 26, 2021 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today...

4 weeks ago - GlobeNewsWire

Affimed to Report Second Quarter 2021 Financial Results & Corporate Update on September 8, 2021

HEIDELBERG, Germany, Aug. 23, 2021 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today...

1 month ago - GlobeNewsWire

Will Affimed N.V. (AFMD) Report Negative Q2 Earnings?

Affimed N.V. (AFMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

1 month ago - Zacks Investment Research

Affimed Announces Publication of Comprehensive Preclinical Data Demonstrating the Therapeutic Potential of AFM24 in E...

HEIDELBERG, Germany, July 30, 2021 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, annou...

1 month ago - GlobeNewsWire

3 Former Penny Stocks With Bullish Analysts & Price Targets Up To 120%

Former penny stocks biotech analysts are bullish on right now. The post 3 Former Penny Stocks With Bullish Analysts & Price Targets Up To 120% appeared first on Penny Stocks to Buy, Picks, News and Info...

Other symbols:GTBPOCGN
2 months ago - PennyStocks

3 Biotech Stocks That Could Double Soon

Wall Street analysts following these drugmakers think they can produce big gains in a short time frame.

Other symbols:ALLKDCPH
2 months ago - The Motley Fool

Affimed Reports First Quarter 2021 Financial Results and Highlights Operational Progress

HEIDELBERG, Germany, July 01, 2021 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today...

2 months ago - GlobeNewsWire

Affimed Earnings Preview

Affimed (NASDAQ:AFMD) announces its next round of earnings this Thursday, July 01. Here is Benzinga's look at Affimed's Q1 earnings report.

2 months ago - Benzinga

Affimed to Report First Quarter 2021 Financial Results & Corporate Update July 1, 2021

HEIDELBERG, Germany, June 22, 2021 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today...

3 months ago - GlobeNewsWire

Affimed Announces Appointment of Uta Kemmerich-Keil to its Supervisory Board

HEIDELBERG, Germany, June 16, 2021 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today...

3 months ago - GlobeNewsWire

Affimed to Present at the Jefferies Virtual Healthcare Conference 2021

Heidelberg, Germany, May 26, 2021 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that its...

3 months ago - GlobeNewsWire

Affimed Announces Virtual Annual General Meeting of Shareholders

Heidelberg, Germany, May 20, 2021 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that its...

4 months ago - GlobeNewsWire

Affimed's AFM13 In Combination With NK Cells Show Improved Tumor Recognition, Killing In Preclinical Studies

Affimed NV (NASDAQ: AFMD) has announced the publication of in vitro and in vivo research of its lead innate cell engager (ICE), AFM13 (CD16A/CD30), combined with healthy donor-derived Natural killer (NK...

4 months ago - Benzinga

Could Affimed Be a Millionaire-Maker Stock?

This biotech stock has already produced some big returns this year.

4 months ago - The Motley Fool

Affimed Announces Publication of Preclinical Data in Clinical Cancer Research Supporting Therapeutic Potential of AFM...

AFM13 in combination with natural killer (NK) cells demonstrated improved tumor recognition and enhanced tumor cell killing in vitro and in vivo.

4 months ago - GlobeNewsWire

Affimed (AFMD) Enters Overbought Territory

Affimed (AFMD) has moved higher as of late, but there could definitely be trouble on the horizon for this company

4 months ago - Zacks Investment Research

Why Affimed N.V. Stock Dropped Today

The company's latest quarterly update was less than impressive.

5 months ago - The Motley Fool

Affimed Reports 2020 Financial Results and Highlights Recent Operational Progress

Heidelberg, Germany, April 15, 2021 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today reported financi...

5 months ago - GlobeNewsWire

Affimed Highlights the Potential of its Innate Cell Engager AFM24 as EGFR-targeting Therapy for Solid Tumors as Monot...

Heidelberg, Germany, April 12, 2021 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announces pre-clinical...

5 months ago - GlobeNewsWire

Here's Why Shares of Affimed Skyrocketed Today

A 100% response rate is impressive, albeit in just four patients.

5 months ago - The Motley Fool

Affimed Stock Jumps After Natural Killer Cells With AFM13 Show Clinical Responses, Minimal Toxicity

Affimed NV (NASDAQ: AFMD) has announced initial clinical data from an investigator-sponsored study evaluating cord blood-derived natural killer (cbNK) cells pre-complexed with Affimed's innate cell enga...

5 months ago - Benzinga